Smad3 linker phosphorylation attenuates Smad3 transcriptional activity and TGF-β1/Smad3-induced epithelial-mesenchymal transition in renal epithelial cells

Biochemical and Biophysical Research Communications

Volumn 427, Issue 3, 2012, Pages 593-599

  Bae, Eunjin ^a,b   Kim, Seong Jin ^a   Hong, Suntaek ^b   Liu, Fang ^c,d   Ooshima, Akira ^a  

^a CHA University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Renal fibrosis; Smad3 phosphorylation; TGF 1 induced EMT

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FIBRONECTIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

CELL LINE; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; HUMANS; KIDNEY TUBULES; MUTATION; PHOSPHORYLATION; SMAD3 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84867878601     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.103     Document Type: Article

References (34)

1. Eddy A.A., Fogo A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006, 17:2999-3012.
2. Wang W., Koka V., Lan H.Y. Transforming growth factor-β1 and Smad signalling in kidney diseases Nephrology. Wiley Online Library 2005, 48-56.
3. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003, 577-584.
4. Hills C.E., Squires P.E. The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 2011.
5. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 2003, 112:1776-1784.
6. Furukawa F., Matsuzaki K., Mori S., Tahashi Y., Yoshida K., Sugano Y., Yamagata H., Matsushita M., Seki T., Inagaki Y. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003, 38:879-889.
7. Verrecchia F., Chu M.L., Mauviel A. Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 2001, 276:17058-17062.
8. Inazaki K., Kanamaru Y., Kojima Y., Sueyoshi N., Okumura K., Kaneko K., Yamashiro Y., Ogawa H., Nakao A. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int. 2004, 66:597-604.
9. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 2003, 112:1486-1494.
10. Alarcon C., Zaromytidou A.I., Xi Q., Gao S., Yu J., Fujisawa S., Barlas A., Miller A.N., ManovaTodorova K., Macias M.J. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-β pathways. Cell 2009, 139:757-769.
11. Aragon E., Goerner N., Zaromytidou A.I., Xi Q., Escobedo A., Massague J., Macias M.J. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Gene. Dev. 2011, 25:1275-1288.
12. Datto M.B., Frederick J.P., Pan L., Borton A.J., Zhuang Y., Wang X.F. Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction. Mol. Cell. Biol. 1999, 19:2495-2504.
13. Guo X., Ramirez A., Waddell D.S., Li Z., Liu X., Wang X.F. Axin and GSK3-β control Smad3 protein stability and modulate TGF-β signaling. Gene. Dev. 2008, 22:106-120.
14. Kamaraju A.K., Roberts A.B. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-β-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 2005, 280:1024-1036.
15. Kim S.G., Kim H.A., Jong H.S., Park J.H., Kim N.K., Hong S.H., Kim T.Y., Bang Y.J. The endogenous ratio of Smad2 and Smad3 influences the cytostatic function of Smad3. Mol. Biol. Cell 2005, 16:4672-4683.
16. Kretzschmar M., Doody J., Timokhina I., Massague J. A mechanism of repression of TGF-β/Smad signaling by oncogenic Ras. Gene. Dev. 1999, 13:804.
17. Liu F. Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev. 2006, 17:9-17.
18. Liu F., Matsuura I. Perspectives inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle 2005, 4:63-66.
19. Matsuura I., Denissova N.G., Wang G., He D., Long J., Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004, 430:226-231.
20. Matsuura I., Wang G., He D., Liu F. Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry 2005, 44:12546-12553.
21. Mori S., Matsuzaki K., Yoshida K., Furukawa F., Tahashi Y., Yamagata H., Sekimoto G., Seki T., Matsui H., Nishizawa M. TGF-β and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004, 23:7416-7429.
22. Wrighton K.H., Lin X., Feng X.H. Phospho-control of TGF-β superfamily signaling. Cell Res. 2008, 19:8-20.
23. Prokova V., Mavridou S., Papakosta P., Kardassis D. Characterization of a novel transcriptionally active domain in the transforming growth factor β-regulated Smad3 protein. Nucleic Acids Res. 2005, 33:3708-3721.
24. Wang G., Long J., Matsuura I., He D., Liu F. The Smad3 linker region contains a transcriptional activation domain. Biochem. J. 2005, 386:29.
25. Ma L.J., Fogo A.B. PAI-1 and kidney fibrosis. Front. Biosci. 2009, 14:2028.
26. Fujimoto M., Maezawa Y., Yokote K., Joh K., Kobayashi K., Kawamura H., Nishimura M., Roberts A.B., Saito Y., Mori S. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 2003, 305:1002-1007.
27. Li J., Qu X., Bertram J.F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 2009, 175:1380-1388.
28. Li J., Qu X., Yao J., Caruana G., Ricardo S.D., Yamamoto Y., Yamamoto H., Bertram J.F. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:2612-2624.
29. Tu Y., Wu T., Dai A., Pham Y., Chew P., de Haan J.B., Wang Y., Toh B.H., Zhu H., Cao Z. Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy. Kidney Int. 2010, 79:199-209.
30. Tang L.Y., Yamashita M., Coussens N.P., Tang Y., Wang X., Li C., Deng C.X., Cheng S.Y., Zhang Y.E. Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3. EMBO. J. 2011, 30:4777-4789.
31. Heyer J., Escalante-Alcalde D., Lia M., Boettinger E., Edelmann W., Stewart C.L., Kucherlapati R. Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. Proc. Natl. Acad. Sci. USA 1999, 96:12595.
32. Nomura M., Li E. Smad2 role in mesoderm formation, left-light patterning and craniofacial development. Nature 1998, 393:786-790.
33. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., Roberts A.B., Deng C. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO. J. 1999, 18:1280-1291.
34. Meng X.M., Huang X.R., Chung A.C.K., Qin W., Shao X., Igarashi P., Ju W., Bottinger E.P., Lan H.Y. Smad2 protects against TGF-β/Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 2010, 21:1477-1487.